Difference between revisions of "Maprotiline-citalopram"
From Psychiatrienet
(Created page with '{{Drugswitch | from = maprotiline | to = citalopram | stop = * '''Before day 0:''' gradually reduce dosage of maprotiline to a maximum of 75 mg/day. * '''Day 1:''' reduce dos...') |
(No difference)
|
Revision as of 20:55, 5 May 2009
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from maprotiline to citalopram.[1] [2]
Stop maprotiline - Before day 0: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
- Day 1: reduce dosage of maprotiline to 50 mg/day.
- Day 3: reduce dosage of maprotiline to 25 mg/day.
Start citalopram- Day 1: simultaneously start administration of citalopram/escitalopram in a normal dosage of 20 mg/day, resp. 10 mg/day.
- Day 8: stop administration of maprotiline and continue administration of citalopram/escitalopram.
More information- Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
- Citalopram/escitalopram are a weak inhibitor of CYP2D6, which metabolizes maprotiline.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
